Cargando…
Current Evidence on Abuse and Misuse of Gabapentinoids
This review summarizes current evidence on the abuse and misuse of the gabapentinoids pregabalin and gabapentin. Pharmacovigilance studies, register-based studies, surveys, clinical toxicology studies, and forensic toxicology studies were identified and scrutinized with the goal to define the proble...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686181/ https://www.ncbi.nlm.nih.gov/pubmed/32857333 http://dx.doi.org/10.1007/s40264-020-00985-6 |
_version_ | 1783613291025661952 |
---|---|
author | Hägg, Staffan Jönsson, Anna K. Ahlner, Johan |
author_facet | Hägg, Staffan Jönsson, Anna K. Ahlner, Johan |
author_sort | Hägg, Staffan |
collection | PubMed |
description | This review summarizes current evidence on the abuse and misuse of the gabapentinoids pregabalin and gabapentin. Pharmacovigilance studies, register-based studies, surveys, clinical toxicology studies, and forensic toxicology studies were identified and scrutinized with the goal to define the problem, identify risk factors, and discuss possible methods to reduce the potential for abuse and misuse. Studies found that gabapentinoids are abused and misused and that individuals with a history of psychiatric disorders or substance use disorder seem to be at high risk. Moreover, some evidence supports the notion that patients with opioid use disorders may be at an increased risk of abusing gabapentinoids. Available evidence also suggests that abuse and misuse are more frequent in users of pregabalin compared with users of gabapentin. Health professionals and prescribers should be aware of the risk for misuse of pregabalin and gabapentin, which eventually could lead to abuse, substance dependence, and intoxications. Prescribing to patients belonging to risk populations such as those with psychiatric disorders or substance use disorder should be avoided if possible and, if prescribed, signs of misuse and abuse should be monitored. |
format | Online Article Text |
id | pubmed-7686181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-76861812020-11-30 Current Evidence on Abuse and Misuse of Gabapentinoids Hägg, Staffan Jönsson, Anna K. Ahlner, Johan Drug Saf Review Article This review summarizes current evidence on the abuse and misuse of the gabapentinoids pregabalin and gabapentin. Pharmacovigilance studies, register-based studies, surveys, clinical toxicology studies, and forensic toxicology studies were identified and scrutinized with the goal to define the problem, identify risk factors, and discuss possible methods to reduce the potential for abuse and misuse. Studies found that gabapentinoids are abused and misused and that individuals with a history of psychiatric disorders or substance use disorder seem to be at high risk. Moreover, some evidence supports the notion that patients with opioid use disorders may be at an increased risk of abusing gabapentinoids. Available evidence also suggests that abuse and misuse are more frequent in users of pregabalin compared with users of gabapentin. Health professionals and prescribers should be aware of the risk for misuse of pregabalin and gabapentin, which eventually could lead to abuse, substance dependence, and intoxications. Prescribing to patients belonging to risk populations such as those with psychiatric disorders or substance use disorder should be avoided if possible and, if prescribed, signs of misuse and abuse should be monitored. Springer International Publishing 2020-08-28 2020 /pmc/articles/PMC7686181/ /pubmed/32857333 http://dx.doi.org/10.1007/s40264-020-00985-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Article Hägg, Staffan Jönsson, Anna K. Ahlner, Johan Current Evidence on Abuse and Misuse of Gabapentinoids |
title | Current Evidence on Abuse and Misuse of Gabapentinoids |
title_full | Current Evidence on Abuse and Misuse of Gabapentinoids |
title_fullStr | Current Evidence on Abuse and Misuse of Gabapentinoids |
title_full_unstemmed | Current Evidence on Abuse and Misuse of Gabapentinoids |
title_short | Current Evidence on Abuse and Misuse of Gabapentinoids |
title_sort | current evidence on abuse and misuse of gabapentinoids |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686181/ https://www.ncbi.nlm.nih.gov/pubmed/32857333 http://dx.doi.org/10.1007/s40264-020-00985-6 |
work_keys_str_mv | AT haggstaffan currentevidenceonabuseandmisuseofgabapentinoids AT jonssonannak currentevidenceonabuseandmisuseofgabapentinoids AT ahlnerjohan currentevidenceonabuseandmisuseofgabapentinoids |